Skaggs School of Pharmacy and Pharmaceutical Sciences, 8784University of California San Diego, La Jolla, CA, USA.
Department of Pediatrics, School of Medicine, 8784University of California San Diego, La Jolla, CA, USA.
Perit Dial Int. 2021 Mar;41(2):202-208. doi: 10.1177/0896860820950924. Epub 2020 Aug 31.
Current pediatric International Society for Peritoneal Dialysis guidelines for initial treatment of peritoneal dialysis (PD)-associated peritonitis suggest either monotherapy with cefepime or double therapy with first-generation cephalosporin or glycopeptide and ceftazidime or aminoglycoside. When using vancomycin, the intraperitoneal (IP) recommended pediatric loading dosage is 1000 mg/L of dialysate. This is based on adult pharmacokinetic (PK) studies and roughly translates to the adult recommendation where 30 mg/kg in 2 L is approximately 1000 mg/L. However, since the dialysate volume in pediatric patients is normalized to body surface area and not weight, the current recommended dosing can result in high vancomycin exposure in children. Vancomycin can potentially cause adverse effects. We aimed to determine if the IP vancomycin dosing of 1000 mg/L was causing elevated vancomycin levels and to offer possible dosing recommendations based on PK modeling and simulation.
Retrospective review of pediatric patients who had been treated with IP vancomycin for PD-associated peritonitis. Vancomycin levels obtained for clinical monitoring were analyzed using NONMEM to generate population and individual (empiric Bayesian) estimates of vancomycin PK parameters and estimated peak levels. Predicted vancomycin peaks were also simulated from virtual pediatrics patients 3-70 kg following various dosing strategies.
Six episodes of peritonitis in three patients were analyzed. In the two episodes treated with 1000 mg/L, the first vancomycin levels (h post) were 95.6 ug/mL (3) and 49 (33) and following 500 mg/L were 33.2 (11), 30.2 (11), 23.6 (24), and 22.1 (11). All patients were cured of their peritonitis without the need for catheter removal. Based on our population PK model, a 1000 mg/L IP vancomycin loading dose will typically result in peak > 50 mg/L in patients weighing <35 kg and >60 mg/L in patients <15 kg. Vancomycin levels will remain above 20 mg/L for over 2 days without additional vancomycin dosing.
The data suggest that a loading dose of vancomycin 1000 mg/L leads to higher than desired vancomycin levels and should be lowered. A 500 mg/L loading dosing appears more appropriate and needs further study.
目前,国际儿科腹膜透析学会(ISPD)关于腹膜透析(PD)相关性腹膜炎初始治疗的指南建议,可选择头孢吡肟单药治疗,或选择第一代头孢菌素或糖肽类联合头孢他啶或氨基糖苷类的双联治疗。当使用万古霉素时,建议腹腔内(IP)的儿童负荷剂量为 1000mg/L 的透析液。这一剂量是基于成人药代动力学(PK)研究得出的,大致相当于成人推荐剂量,即 2L 中 30mg/kg 约为 1000mg/L。然而,由于儿科患者的透析液体积是根据体表面积而不是体重来归一化的,因此目前推荐的剂量可能会导致儿童万古霉素暴露水平升高。万古霉素可能会引起不良反应。我们旨在确定 IP 万古霉素 1000mg/L 的给药剂量是否会导致万古霉素水平升高,并根据 PK 建模和模拟提供可能的给药建议。
回顾性分析了接受 IP 万古霉素治疗 PD 相关性腹膜炎的儿科患者。对用于临床监测的万古霉素水平进行分析,采用 NONMEM 生成万古霉素 PK 参数的群体和个体(经验贝叶斯)估计值和估计的峰值水平。还根据各种给药方案,从虚拟儿科患者(3-70kg)模拟预测的万古霉素峰值。
分析了 3 名患者的 6 次腹膜炎发作。在接受 1000mg/L 万古霉素治疗的 2 个发作中,第 1 个万古霉素水平(h 后)分别为 95.6μg/mL(3)和 49(33),而在接受 500mg/L 万古霉素治疗后,分别为 33.2(11)、30.2(11)、23.6(24)和 22.1(11)。所有患者的腹膜炎均治愈,无需拔除导管。基于我们的群体 PK 模型,体重<35kg 的患者接受 1000mg/L IP 万古霉素负荷剂量后,通常会导致峰浓度>50mg/L,体重<15kg 的患者会导致峰浓度>60mg/L。不进行额外万古霉素给药,万古霉素水平将超过 2 天保持在 20mg/L 以上。
数据表明,万古霉素 1000mg/L 的负荷剂量会导致高于预期的万古霉素水平,应予以降低。500mg/L 的负荷剂量似乎更合适,需要进一步研究。